> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Revvity Raises 2026 Outlook As Adjusted Operating Margin Climbs To 28.7%
- URL: https://www.bullished.co/revvity-raises-2026-outlook-as-adjusted-operating-margin-climbs-to-28-7-b75ab61e/
- Published: 2026-11-03T13:57:52.000Z
- Updated: 2026-11-03T13:57:52.000Z
- Description: The lab-science company posted third-quarter revenue of $729 million and now sees full-year adjusted earnings of $5.40-$5.45 a share.
- Author: Matteo Parrino
- Tags: Earnings, RVTY, Industry: Healthcare

[Revvity](https://www.bullished.co/tag/rvty/), which makes instruments, reagents, software and services for researchers and clinical labs, raised its full-year guidance after reporting third-quarter [revenue of $729 million](https://www.sec.gov/Archives/edgar/data/0000031791/000003179126000031/q32026pressrelease.htm?ref=bullished.co), up from $699 million a year earlier. CEO Prahlad Singh said "broad-based growth and strong execution drove results meaningfully ahead of our expectations."

## Margins widen in both segments

Pro forma revenue, which strips out the Chinese immunodiagnostics business Revvity has agreed to sell, was $710 million, up 7% from $660 million. Pro forma organic growth was also 7%.

Adjusted operating margin reached 28.7%, from 26.1% a year ago. Adjusted earnings per share from continuing operations [rose to $1.38](https://finance.yahoo.com/markets/stocks/articles/revvity-rvty-tops-q3-earnings-112503267.html?.tsrc=rss&ref=bullished.co) from $1.18, and earnings under standard accounting climbed to $0.56 from $0.41.

Life Sciences revenue was $380 million, against $343 million. Pro forma revenue there rose 11%, and organic revenue rose 9%. Its adjusted operating margin was 31.5%, from 29.5%.

Diagnostics revenue was $349 million, down from $356 million as reported. Pro forma revenue rose 4% and pro forma organic revenue rose 5%. Its adjusted margin jumped to 29.9% from 25.1%.

## The new full-year guidance

For 2026, Revvity forecasts pro forma revenue of [about $2.86 billion](https://wtop.com/national/2026/11/revvity-q3-earnings-snapshot/?ref=bullished.co), pro forma organic growth of about 5% and pro forma adjusted earnings per share of $5.40-$5.45\. Guidance excludes the China unit.

Revvity's business spans two segments. Life Sciences serves pharmaceutical, biotech and academic customers, and Diagnostics sells to hospitals and medical labs.

## The China sale and a cleaner balance sheet

Revvity signed a [definitive agreement](https://www.sec.gov/Archives/edgar/data/0000031791/000003179126000031/pki-20261103.htm?ref=bullished.co) on July 31 to sell its China immunodiagnostics business for up to $200 million, subject to adjustments and conditions. That unit made up about 6% of 2025 revenue. Management believes it is probable the deal closes by the end of 2027.

In the quarter, the company paid $571 million on its senior unsecured notes. Its balance sheet at quarter-end showed no current portion of long-term debt, against $589 million at the end of 2025.

Revvity holds its Investor Day on Friday, November 13, at 9:00 a.m. ET.

Management will lay out its business initiatives and financial outlook at the November 13 Investor Day.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — REVVITY, INC. (RVTY)](https://www.sec.gov/Archives/edgar/data/0000031791/000003179126000031/pki-20261103.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit q32026pressrelease.htm — REVVITY, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000031791/000003179126000031/q32026pressrelease.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit q32026proformafinancialsta.htm — REVVITY, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000031791/000003179126000031/q32026proformafinancialsta.htm?ref=bullished.co) — SEC EDGAR
- [Revvity: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/revvity-q3-earnings-snapshot-111126996.html?ref=bullished.co) — Associated Press
- [Revvity (RVTY) Tops Q3 Earnings and Revenue Estimates](https://finance.yahoo.com/markets/stocks/articles/revvity-rvty-tops-q3-earnings-112503267.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Revvity: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/11/revvity-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [Revvity: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/revvity-q3-earnings-snapshot/616-32ca4230-7436-482d-b5ee-d7d928557288?ref=bullished.co) — Associated Press
- [Revvity: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/revvity-q3-earnings-snapshot/616-32ca4230-7436-482d-b5ee-d7d928557288?ref=bullished.co) — Associated Press

### More on Revvity

- [Revvity Says AI Demand Is Spreading Past Screening, Holds Detail For Its November 13 Investor Day](https://www.bullished.co/revvity-says-ai-demand-is-spreading-past-screening-holds-detail-for-its-november-13-5f27f96f/)

[All Revvity (RVTY) coverage →](https://www.bullished.co/tag/rvty/)